Axio BioPharma’s new report examines the structural barriers preventing AI from scaling beyond pilots in biomanufacturing, and what organizations need to build now to close the gap between dashboards and decisions.
Most biomanufacturing organizations have started implementing AI. Very few have scaled it.
AI adoption in life sciences has accelerated faster than governance, infrastructure, and organizational readiness. The result: pilots that cannot move to production, models that cannot cross organizational boundaries, and investments that produce dashboards instead of decisions.
This report looks at the structural reasons and provides a framework for addressing them.
Four structured parts, grounded in the regulatory stack and the operational realities of running biomanufacturing today.
The specific integration, governance, and incentive failures that keep AI initiatives from reaching production.
A six-level framework for assessing AI readiness overlaying DPMM and DISCO to show where you are and what comes next.
How outsourcing relationships determine whether AI scales or stays siloed and three CDMO operating archetypes to evaluate against.
A cross-organizational architecture that preserves IP, respects regulatory constraints, and enables cross-site learning without centralized data pooling.
What DPMM Level 3+ actually enables and how digital twins move from advisory tools to operational infrastructure.
From GMP expectations to CDMO service productization to federated learning as the default cross-company approach.
Six actions, in order, with clear ownership for organizations ready to move from strategy to implementation.
Yield, cycle time, deviation rates, release lead time. Where AI is economically meaningful and how to build the case for it.
Which use cases are feasible at your current DPMM level and what you need to build to advance to the next one.
EMA, FDA, EU GMP Annex 22 (draft), and ISPE GAMP AI; what the converging regulatory stack means for your model lifecycle.
This report is essential reading for CDMOs building AI-enabled service offerings, and outsourcing decision-makers evaluating digital readiness in manufacturing partners.
Authored by the Axio BioPharma team, drawing on cross-ecosystem conversations with sponsors, CDMOs, equipment vendors, and regulators.
The report introduces BAMI (Biomanufacturing AI Maturity Index) a new six-level maturity framework that overlays BioPhorum's DPMM and DISCO Playbook with an AI-specific lens, giving organizations a structured way to assess what they can realistically deploy today and what they need to build toward.
AI in Biomanufacturing: How operating models, digital twins, and federated intelligence are reshaping the biologics manufacturing ecosystem is available now as a free report from Axio BioPharma.
No upsell. Axio BioPharma will not share your information.
